COVID-19 Vaccines in Different Countries - Moderna

According to the latest media reports, Moderna has already applied to the US “Food and Drug Administration (FDA) for an emergency use authorization” of its mRNA-1273 COVID-19 vaccine. The company expects to start producing the vaccines from December 21, 2020, if it receives FDA’s authorization. Moderna has announced plans to produce “500 million to 1 billion doses globally in 2021.” Russia has developed its own COVID-19 vaccine called Sputnik V at a fraction of the cost of Moderna’s vaccine. China has partnered with private companies other than Moderna for developing vaccines within the country. Consequently, there are no publicly available reports regarding the availability of Moderna’s COVID-19 vaccine in both Russia and China. However, Brazil, India, Mexico, Japan, and Singapore are expected to receive doses of Moderna’s vaccine during the first half of 2021.

Also, check out our research on;


  • Russia has announced that it will produce its Sputnik V COVID-19 vaccine at a fraction of the cost of its rival vaccines, developed by Pfizer-BioNTech and Moderna. According to the Russian Direct Investment Fund (RDIF), “The cost of one dose of the Sputnik V vaccine for international markets will be less than $10.” Russian citizens will receive the vaccine for free.
  • Compared to the low cost of the Sputnik V vaccine, the “Pfizer-BioNTech vaccine is expected to cost around $20 per dose,” while the vaccine developed by Moderna is expected to cost $25-$37 per dose. Russia intends to produce 1 billion doses of the Sputnik V vaccine for the global market in 2021.
  • According to the results of the latest clinical trials, the Sputnik V vaccine has an efficacy rate of 91.4% after 28 days and 95% after 42 days.


  • The Brazilian government has recently signed a non-binding letter of intent for purchasing the COVID-19 vaccine developed by Moderna. It has also signed similar deals with Pfizer, India’s Bharat Biotech, Janssen, and the Russian Direct Investment Fund. The Brazilian government has an existing deal with AstraZeneca for its COVID-19 vaccine.
  • The Brazilian health minister has promised to vaccinate the entire Brazilian population in 2021. On December 10, 2020, Brazil’s Sao Paulo state started manufacturing Sinovac’s COVID-19 vaccine at its Butantan Institute. The state government intends to roll out the vaccine for the public from January 25, 2021. From these developments, it is expected that Moderna’s COVID-19 vaccine will be available in Brazil in the first half of 2021.


  • The Indian government is currently holding talks with Moderna about the COVID-19 vaccine being developed by the company. However, Moderna has not yet shared details with the Indian government regarding the ultra-cold storage solutions needed for storing the vaccine doses.
  • Moderna’s COVID-19 vaccine has been developed based on mRNA technology and “can be stored at normal fridge temperatures of 2 to 8 degrees Celsius for 30 days” and at a temperature of minus 20 degrees Celsius for six months.
  • According to Moderna’s CEO Stephane Bancel, government approval for the COVID-19 vaccine is expected in the “late first quarter or early second quarter of 2021.” Looking at the timeline, industry experts predict that India will receive the first doses of Moderna’s COVID-19 vaccine in March-April 2021.


  • Moderna has submitted a proposal to the government of Mexico to supply 39 million doses of its COVID-19 vaccine starting in April 2021.
  • According to Marcelo Ebrard, the Foreign Minister of Mexico, similar proposals have also been received from Sinovac, CureVac, Novavax, and Janssen. However, Pfizer-BioNTech’s COVID-19 vaccine is expected to be the first vaccine to be administered to the public in Mexico.


  • Moderna has partnered with Takeda Pharmaceutical Co., Ltd and the Japanese government to supply 50 million doses of its mRNA-1273 COVID-19 vaccine to Japan. The first batch of the vaccine is expected to reach Japan “during the first half of 2021.


  • Moderna has finalized a deal with “Singapore’s Ministry of Health (MOH)” to supply its mRNA-1273 COVID-19 vaccine to Singapore in the first half of 2021. However, Moderna has not disclosed any details surrounding the finalized agreement.
  • The Singaporean government has already approved the use of Pfizer-BioNTech’s COVID-19 vaccine in the country. The first batch of this vaccine is expected to be available in Singapore by the end of December 2020.

United States (US)

  • The US is expected to receive doses of Moderna’s COVID-19 vaccine by December 2020. According to Moderna, the US will receive 20 million doses by December, and additional 100 million doses by the first quarter of 2021.
  • New York expects to receive 346,000 doses, whereas Michigan expects 173,000 Moderna vaccines.


  • Canada expects to receive Moderna’s vaccine by March 2021.
  • The territory expects to receive about 51,000 doses of the vaccine, which is enough to distribute to 75% of the country’s residents aged 18 and over.

United Kingdom (UK)

  • The UK expects to receive Moderna’s vaccine by early spring 2021.
  • The country expects to receive 7 million doses of the vaccine, which is estimated to be enough for approximately 3.5 million people.

European Union (EU)

  • The EU is expected to receive 160 million doses of Moderna’s vaccine.
  • France will roll-out a three-phased vaccination strategy in January 2021.
  • Germany expects to receive the vaccine in the first quarter of 2021 at the earliest.
  • Italy expects to receive doses of the vaccine in January 2021.
  • Spain is expected to receive the vaccine doses in early January.
Glenn is the Lead Operations Research Analyst at The Digital Momentum with experience in research, statistical data analysis and interview techniques. A holder of degree in Economics. A true specialist in quantitative and qualitative research.

COVID-19 Vaccines in Different Countries – Janssen

Previous article

COVID-19 Vaccines in Different Countries – Novavax

Next article

You may also like


Leave a reply

Your email address will not be published.